Author:
Elavarasi Arunmozhimaran,Goyal Vinay
Reference21 articles.
1. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM, American Academy of Neurology Society, European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.
2. Macdonald TE, Helma CH, Shou Y, Valdez YE, Ticknor LO, Foley BT, et al. Analysis of Clostridium botulinum serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing. Appl Environ Microbiol. 2011;77:8625–34.
3. Scaglione F. Conversion ratio between Botox(R), Dysport(R), and Xeomin(R) in clinical practice. Toxins (Basel). 2016;8:pii:E65.
4. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7:31–9.
5. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155–88.